Edwards Lifesciences Corp
- 取引所
- 米国株
- 国 / 地域
- USA
- 上場日
- 2000年3月27日
- 従業員数
- 16,000
- 公式サイト
- www.edwards.com
総合バリュエーションレンジ · 保守的 $45–$58 / 妥当 $68–$82 / 楽観的 $82–$98。$83.04 時点で 楽観的な本源的価値レンジ内 · 多くの期待を織り込み済み。
レポート公開時 $87.54（2026年5月27日）
データ提供：EODHD、報告通貨で表示。参考情報であり、投資助言ではありません。
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
沿革
Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California, and held its IPO on March 27, 2000. In September 2024 it sold its Critical Care business to BD for $4.2 billion, generating an after-tax gain of about $3.3 billion, making 2025 its first full year operating as a pure structural-heart company. During 2024 it also completed the Innovalve and Endotronix acquisitions, while its proposed JenaValve acquisition was blocked by the FTC, leading to a roughly $99.8 million impairment on a JenaValve bridge loan in 2025.
業界での地位
Edwards Lifesciences is a leading structural-heart-disease device company operating across three continuing segments: TAVR (transcatheter aortic valve replacement), TMTT (transcatheter mitral and tricuspid therapies), and Surgical structural heart. In 2025 continuing-operations revenue was $6.068 billion, comprising TAVR of $4.488 billion, TMTT of $0.551 billion, and Surgical of $1.029 billion, with gross margin around 80%+. Its products include the Edwards SAPIEN valve family, PASCAL, EVOQUE, INSPIRIS, RESILIA, KONECT RESILIA, MITRIS RESILIA, and SAPIEN M3, sold across roughly 100 countries via a direct sales force in the U.S. and direct sales plus independent distributors abroad. Per its 10-K, its main competitors are Medtronic and Abbott in TAVR, Abbott in TMTT, and Medtronic and Abbott in Surgical.
この銘柄のレポートはお使いの言語でまだありません。